• Connect
  • Bookmark Us
  • AF Twitter
  • AF YouTube
  • AF LinkedIn
  • Subscribe
  • Subscription Link
Arent Fox
  • Firm

    • History

    • Awards & Recognitions

    • Diversity

      • Overview
      • Diversity Scholarship
      • Employees on Diversity
      • LGBT Initiative
      • Women’s Leadership Development Initiative
    • Alumni

    • Pro Bono

      • Overview
      • Current Pro Bono Work
      • Community Involvement
      • Pro Bono Newsletter
      • Pro Bono Awards & Honors
      • FAQ: Pro Bono & Working at Arent Fox
    • Leadership

      • Firm Management
      • Administrative Leadership
  • Deals & Cases

  • People

  • Practices & Industries

    • Practices

      • Advertising, Promotions & Data Security
      • Government Relations
      • Antitrust & Competition Law
      • Health Care
      • Appellate
      • Insurance & Reinsurance
      • Bankruptcy & Financial Restructuring
      • Intellectual Property
      • Commercial Litigation
      • International Trade
      • Communications, Technology & Mobile
      • Labor & Employment
      • Construction
      • Municipal & Project Finance
      • Consumer Product Safety
      • OSHA
      • Corporate & Securities
      • Political Law
      • ERISA
      • Real Estate
      • Environmental
      • Tax
      • FDA Practice (Food & Drug)
      • Wealth Planning & Management
      • Finance
      • White Collar & Investigations
      • Government Contractor Services
    • Industries

      • Automotive
      • Energy Law & Policy
      • Fashion, Luxury Goods & Retail
      • Government Real Estate & Public Buildings
      • Hospitality
      • Life Sciences
      • Long Term Care & Senior Living
      • Media & Entertainment
      • Medical Devices
      • Nonprofit
      • Sports
  • Newsroom

    • Alerts

    • Events

    • Media Mentions

    • Press Releases

    • Social Media

    • Subscribe

  • Careers

    • Lawyers

    • Law Students

    • Professional Staff

  • Contact

    • Washington, DC

    • New York, NY

    • Los Angeles, CA

    Alerts

    • Newsroom Overview
      • Alerts

        Alerts by Criteria

        E.g., 1 / 21 / 2013
        E.g., 1 / 21 / 2013
      • Events
      • Media Mentions
      • Press Releases
      • Social Media
      • Subscribe

    You are here

    Home » Newsroom » Alerts

    Share

    • Printer-friendly version
    • Send by email
    • A Title
    • A Title
    • A Title
    • A
    • A
    • A

    FDA Ordered to Revisit Decision Not to Ban Use of Certain Antibiotics in Animal Feed

    June 12, 2012

    On June 4, 2012, Judge Theodore Katz of the US District Court for the Southern District of New York ordered the Food and Drug Administration (FDA) to revisit its April 2012 decision not to ban the use of approximately 200 products, including certain antibiotics, in animal feed. Judge Katz also criticized FDA for its decision to rely on the animal feed industry to voluntarily limit the use of such drugs rather than prohibiting their use. The ruling, which requires FDA to reconsider two Citizen Petitions asking the Agency to withdraw approval of certain antibiotics used in food-producing animals, stated that FDA’s previous denial of both Petitions was “arbitrary and capricious”. Katz said FDA must evaluate the safety risks of the drugs and make a finding that they are unsafe or explain why it will not do so. FDA is expected to appeal the ruling.

    The Court’s ruling is the outcome of suit brought against FDA by the Natural Resources Defense Council and several other health and consumer advocacy groups. In a related decision, the same Court ruled in March 2012 that FDA must follow through on a proposal it made decades ago to ban the use of penicillin and two forms of tetracycline in animal feed.

    In recent years, FDA has been promoting a plan to establish voluntary limits on antibiotics in animal feed. In its most recent effort, FDA began asking drug makers to stop using 200 products for growth promotion in animals and instead use them only to treat diseases. FDA has stated its voluntary plan would result in a more expeditious decline in the use of these antibiotics than, for example, initiating formal rulemaking to withdraw each subject antibiotic from the market.

    The ruling now puts pressure on FDA to either follow the above-noted Court orders or find an alternative regulatory solution amenable to industry, consumer advocates, and Judge Katz. For additional information, please contact Georgia C. Ravitz, Robert G. Edwards, or James H. Hartten at Arent Fox LLP.

    Related People

    • Robert G. Edwards, Ph.D.*
    • James H. Hartten*
    • Georgia Ravitz

    Related Practices

    FDA Practice (Food & Drug)
    • Firm
    • Deals & Cases
    • People
    • Practices & Industries
    • Newsroom
    • Careers
    • Contact

    Footer Main

    • Firm
    • Deals & Cases
    • People
    • Practices & Industries
    • Newsroom
    • Careers
    • Subscribe
    • Alumni
    • Diversity
    • Legal Notice
    • Privacy Policy
    • Social Media Disclaimer
    • Nondiscrimination
    • Site Map
    • Client/Staff Login

    Offices

    • Washington, DC
      1717 K Street, NW
      Washington, DC 20036
      Tel: 202.857.6000
    • New York, NY
      1675 Broadway
      New York, New York 10019
      Tel: 212.484.3900
    • Los Angeles, CA
      555 West Fifth Street, 48th Floor
      Los Angeles, California 90013
      Tel: 213.629.7400
    • © Copyright 2013 Arent Fox LLP. All Rights Reserved.

      Legal Disclaimer
      Contents may contain attorney advertising under the laws of some states. Prior results do not guarantee a similar outcome.